Followers | 17 |
Posts | 2713 |
Boards Moderated | 0 |
Alias Born | 04/30/2011 |
Tuesday, October 28, 2014 8:29:37 AM
Nine Months Ended August 31, 2014 Compared to the Nine Months Ended August 31, 2013
Revenue. Total revenue for the nine months ended August 31, 2014 and August 31, 2013 was $36,988. All of the revenue for the nine months ended August 31, 2014 and August 31, 2013 is from the amortization of deferred revenue under license agreements with Corning and Pfizer.
Operating Expenses. Total operating expenses for the nine months ended August 31, 2014 were $517,679, compared to operating expenses for the nine months ended August 31, 2013 of $1,018,548, representing a decrease of $500,869. This decrease was due to the reversal of $461,000 of stock-based compensation and a decrease of $99,963 in the recognition of other stock-based compensation, offset by an increase of $59,174 in professional and consulting fees and a net increase in other operating expenses of $920.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM